Alfacalcidol-d6
Alfacalcidol-d6 is the deuterium labeled Alfacalcidol. Alfacalcidol is a non-selective VDR activator.
Product Specifications
CAS Number
1641940-94-4
UNSPSC
12352211
Target
VD/VDR
Type
Isotope-Labeled Compounds
Related Pathways
Vitamin D Related/Nuclear Receptor
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease
Purity
98.0
Solubility
10 mM in DMSO|DMSO : ≥ 50mg/mL
Smiles
O[C@H](C/1=C)C[C@H](O)CC1=C\C=C2[C@@](CC[C@@H]3[C@@H](CCCC(C([2H])([2H])[2H])C([2H])([2H])[2H])C)([H])[C@]3(C)CCC\2
Molecular Formula
C27H38D6O2
Molecular Weight
406.67
References & Citations
[1]Shiraishi et al (2000) Alfacalcidol inhibits bone resorption and stmulates formation in an ovariectomized rat model of osteoporosis: Distinct actions from estrogen. Journal of Bone and Mineral Research. 15 770.|[2]Ringe JD, Schacht E. et al. Prevention and therapy of osteoporosis: the roles of plain vitamin D and alfacalcidol. Rheumatol Int. 2004 Jul;24 (4) :189-97.|[3]Ivarsen P, Povlsen JV, Christensen KL.Effect of alfacalcidol on cardiac function in patients with chronic kidney disease stage 4 and secondary hyperparathyroidism: A pilot study.Scand J Urol Nephrol. 2012 Jun 25.|[4]Rianthavorn P, et al. Prevention of bone loss in children receiving long-term glucocorticoids with calcium and alfacalcidol or menatetrenone.J Pediatr Endocrinol Metab. 2012;25 (3-4) :307-12.|[5]Ringe JD, Farahmand P, Schacht E.Alfacalcidol in men with osteoporosis: a prospective, observational, 2-year trial on 214 patients.Rheumatol Int. 2012 Apr 8.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC472106-100 1x 100 µL
Replication Protein A2 (RPA2) (RPA2/2106), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
